Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells
about
Dinosaurs and ancient civilizations: reflections on the treatment of cancerEpigenetic changes during cell transformationThe rebel angel: mutant p53 as the driving oncogene in breast cancer.Neoplasia: the second decade.More targets, more pathways and more clues for mutant p53.p53 induces distinct epigenetic states at its direct target promoters.Macrophage infiltration and genetic landscape of undifferentiated uterine sarcomas.Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon betap53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs.Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes.Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant negative breast cancer xenograft model.Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones.Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component.Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulatorRegulation of hypoxia-inducible factor 1α (HIF-1α) by lysophosphatidic acid is dependent on interplay between p53 and Krüppel-like factor 5.Ultraslow oligomerization equilibria of p53 and its implications.The War on Cancer rages on.Cancer cell-secreted IGF2 instigates fibroblasts and bone marrow-derived vascular progenitor cells to promote cancer progression.The tumor suppressor p53: from structures to drug discovery.p53 and its mutants in tumor cell migration and invasion.p53 inhibits SP7/Osterix activity in the transcriptional program of osteoblast differentiation.A truncated p53 in human lung cancer cells as a critical determinant of proliferation and invasiveness.CAPE Analogs Induce Growth Arrest and Apoptosis in Breast Cancer Cells.Sequential loss of cell cycle checkpoint control contributes to malignant transformation of murine embryonic fibroblasts induced by 20-methylcholanthrene.Ki-67 Contributes to Normal Cell Cycle Progression and Inactive X Heterochromatin in p21 Checkpoint-Proficient Human Cells.PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation.Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1.Ki-67: more than a proliferation marker.p53 and metabolism: from mechanism to therapeutics.Tolerance to sustained activation of the cAMP/Creb pathway activity in osteoblastic cells is enabled by loss of p53
P2860
Q24628746-F52E54D3-775D-4296-8BA7-A63B3AA39273Q27002968-5446005B-A420-4D12-9044-C63966B83E78Q27686765-579038DA-CB2E-4A5F-B2D0-E09F3C35229EQ30484000-C6DCCF93-BC69-4E3F-B824-39E4FFAB9110Q30542607-EAC33CD0-3F15-4944-8062-323C7652F76DQ33376888-E1C91FB2-E374-4972-B24F-A82B0D064FDCQ33752376-4A32163D-A3F8-46FD-8A32-65533BAE1C8FQ34695472-83F3A845-ADFF-40A6-953F-D0ABE5360FB4Q34787898-477C3E14-D2E1-4E9C-A124-66347AC674C4Q34802295-6D2C0774-C96D-4EF5-B285-2AEC9F07F509Q35073239-189F4957-22E9-46A9-8368-57250C6DE48CQ35897417-49266150-1A6A-40A0-8CBC-D669D6AE003CQ36359692-A8328FA7-8801-4AA0-9D9B-9F98AAD4BE5FQ36495792-65A4281F-C304-416F-A1BC-61A6C426FE90Q36917897-BCD276D7-D8C4-4F13-9B5C-9458251A38E2Q36944192-07B76FFA-AF69-452D-8C64-B624DE9393E6Q37092352-13BAEBE4-E382-4A59-A90C-CA5765E9D277Q37132090-D8466EF8-756B-4183-A9AE-A62370B60D39Q37318326-35891310-D1FE-4FFC-8B6F-2E4D6766635DQ37478602-38B10123-B2EB-42D0-8336-CD81512FF1A9Q37642862-55E0458C-E243-4D94-8A0C-E999566254F3Q37762069-FA948A96-13C6-4F11-B800-388F9E5C3E97Q37832072-B728287F-F59D-4E25-B9A5-B147EAE51613Q38640975-D8ED8461-8C12-4204-A5EB-923AFEB3D6AEQ38699698-96166612-8143-4254-A0A7-CE625E05719EQ38851998-61D29970-00EE-4715-BFED-66BADC28C439Q39727223-78D714D7-B808-44A0-BAA0-351E642BF97EQ47725138-4ECFFF02-4E36-431D-83E7-859332216648Q48507317-55BF014B-23BD-4D3D-8C35-7107F4655F8FQ49952370-48BD06E6-B0C9-4E34-B984-B9C722AFE2A6Q50098339-F49BAC9A-9C87-4C28-90AB-9B4C7DFB1293Q55002919-66EEF0FD-8EC2-40EF-B238-D7887DD8746AQ58699629-3F53D4A4-7F30-4F96-93CD-00C247AB36BE
P2860
Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Different mutant/wild-type p53 ...... human mammary epithelial cells
@ast
Different mutant/wild-type p53 ...... human mammary epithelial cells
@en
type
label
Different mutant/wild-type p53 ...... human mammary epithelial cells
@ast
Different mutant/wild-type p53 ...... human mammary epithelial cells
@en
prefLabel
Different mutant/wild-type p53 ...... human mammary epithelial cells
@ast
Different mutant/wild-type p53 ...... human mammary epithelial cells
@en
P2093
P2860
P356
P1433
P1476
Different mutant/wild-type p53 ...... human mammary epithelial cells
@en
P2093
Bernard W Futscher
Damian J Junk
George S Watts
Jesse D Martinez
Marc M Oshiro
P2860
P304
P356
10.1593/NEO.08120
P50
P577
2008-05-01T00:00:00Z